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Abstract: Technical progress in immunohistochemistry (IHC) as
well as the increased utility of IHC for biomarker testing in
precision medicine avails us of the opportunity to reassess
clinical IHC as a laboratory test and its proper characterization
as a special type of immunoassay. IHC, as used in current
clinical applications, is a descriptive, qualitative, cell-based,
usually nonlinear, in situ protein immunoassay, for which the
readout of the results is principally performed by pathologists
rather than by the instruments on which the immunoassay is
performed. This modus operandi is in contrast to other assays
where the instrument also performs the readout of the test result
(eg, nephelometry readers, mass spectrometry readers, etc.). The
readouts (results) of IHC tests are used either by pathologists for
diagnostic purposes or by treating physicians (eg, oncologists)
for patient management decisions, the need for further testing,
or follow-up. This paper highlights the distinction between the
original purpose for which an IHC test is developed and its
subsequent clinical uses, as well as the role of pathologists in the
analytical and postanalytical phases of IHC testing. This paper
is the ﬁrst of a 4-part series, under the general title of “Evolution
of Quality Assurance for Clinical Immunohistochemistry in the
Era of Precision Medicine.”
Key Words: biomarkers, quality assurance, quality control,
validation, immunohistochemistry
(Appl Immunohistochem Mol Morphol 2017;25:4–11)
In the era of precision medicine, biomarker testing usingimmunohistochemistry (IHC) has not only become
more precise but also more complex.1–6 Precision medi-
cine requires precision results, which can only come about
from precision testing. Because of increasing reliance on
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the results of biomarker testing in patient management, a
clear understanding by the pathologist of the tests
themselves that provide this information is critical to
appropriate patient care and thus patient safety.7–9
In this paper, we emphasize the essential role of
“purpose” in the IHC assay:
 that “purpose” is the intended use of an IHC test at
the time that the test was developed,
 that “purpose” is intrinsic to the identity of any
particular IHC test, and
 that classiﬁcation based on “purpose” of the IHC
test is helpful in developing proper quality assurance
tools and clariﬁes the utilities of that test in patient
management in the era of precision medicine.10
IHC AS A QUALITATIVE ASSAY FOR THE IN SITU
DETECTION OF PROTEIN BIOMARKERS
It is essential to recognize that in its most common
application, IHC is a descriptive, threshold-based test. In
this context it is generally unknown to what extent the
relationship between the amount of target protein and
observed intensity of achieved signal is linear.11–14 The
intention is to deliver a “positive” or “negative” signal
where appropriate and meaningful, rather than to mea-
sure the amount of target protein. This mode of appli-
cation is similar to other testing methods that employ
ampliﬁcation such as polymerase chain reaction (PCR)-
based methods, which are also considered as descriptive
or “threshold methodologies.” For example, the intention
of performing PCR testing is to demonstrate whether
DNA or RNA sequences of interest are detected or not,
while in IHC the focus is on whether a target protein-
based biomarker is detected or not; however, both need to
be demonstrated at clinically relevant sensitivity and
speciﬁcity, which is achieved through validation.15
Today the results of IHC testing are increasingly
applied as biomarkers. The term “biomarker” (or bio-
logical marker) is broadly deﬁned as any biological or
physiological moiety that is used to identify disease, guide
targeted therapy or monitor for reoccurrence.16,17 Al-
though the nomenclature is not fully standardized, the
National Institutes of Health working group’s deﬁnition of
a biomarker is more rigid and requires that a biomarker
can be objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or
pharmacologic response to a therapeutic intervention.18
The American Association of Pharmaceutical Scientists
and the US Clinical Ligand Society have identiﬁed 4 gen-
eral classes of biomarker assays: (i) deﬁnite quantitative
assays (eg, mass spectrometry; reference standard is well
deﬁned and fully representative of the endogenous bio-
marker); (ii) relative quantitative assays (eg, ligand-binding
assay; reference standards may not be available in a de-
ﬁned form or fully representative of an endogenous bio-
marker); (iii) quasiquantitative assays (eg, qRT-PCR,
which does not employ the use of a calibration standard,
but has a continuous response and the result is expressed in
terms of a characteristic of the test sample, and (iv) qual-
itative assays (eg, PCR or IHC; these tests generate cate-
gorical data that lack proportionality to the amount of
analyte in a sample.8 Qualitative assays such as PCR or
IHC typically generate nominal results (eg, presence or
absence of target analyte; eg, PCR test positive for My-
cobacterium tuberculosis or IHC test positive for S-100 or
anaplastic lymphoma kinase (ALK)).8 The results of
qualitative assays may also be expressed in ordinal form by
use of scoring scales for readout (eg, 0 to 3+ for HER2
IHC in breast cancer). Some IHC tests may have complex
readout rules and require either percentage estimate or
direct cell counting with predeﬁned cutoﬀ points for what
is considered a “positive” or a “negative” result. An ex-
ample of this approach is the PD-L1 IHC 22C3 PharmDx
assay (Dako/Agilent Technologies, Canada) where the
cutoﬀ point for a positive test is 50% positive tumor cells.19
Although the percentage of positive cells is reported, no
measurement is involved as the overall result is based on
identifying the threshold between a positive cell (any
membranous staining of tumor cells) versus a negative cell
(no staining of tumor cell membrane). Ultimately, there-
fore, this biomarker is descriptive and qualitative, rather
than quantitative in a strict sense.
The future development of IHC and related methods
for protein quantiﬁcation, in the sense of measurement of
in situ protein, is beyond the purview this paper and
functional capability of IHC as currently practiced. How-
ever, the qualitative nature of IHC, as used today in clin-
ical practice, does not make IHC biomarkers inferior to
other biomarkers. IHC biomarkers are useful diagnostic,
prognostic, and predictive markers when properly vali-
dated for speciﬁc use.20 Applying identical logic, the PCR
test is a valid biomarker for detection ofM. tuberculosis, or
B or T cell clonality, if the test is properly validated for the
speciﬁed use.21,22 What ultimately makes a laboratory test
“bad” or “good” does not necessarily depend on the level
of quantitation in methodology nor on the sophistication
of the methodology, but rather, on whether or not the test
is properly validated (clinically, diagnostically, and tech-
nically) for the speciﬁed purpose (“ﬁt-for-purpose”).10
“PURPOSE” IS INTRINSIC TO THE IHC TEST
“Purpose” is intrinsic to the identity of every labo-
ratory test, including IHC tests.8,10,23,24 Because of in-
creasing awareness of the need for quality assurance in
every aspect of IHC testing, it is important that the de-
velopment of each IHC-based assay takes into consid-
eration its intended use at the time of its development. This
is particularly relevant to the validation of IHC tests. As
we will show in this series, the type of validation depends
entirely on the purpose for which a test is devel-
oped.10,15,25–27 When the purpose of a test is changed, even
if it identiﬁes the same target molecule, it becomes a dif-
ferent test and therefore its validation requirements should
be revisited. This can be illustrated by considering the use
of antibodies to CD34. Table 1 describes 3 diﬀerent pur-
poses for performing a CD34 IHC test in clinical practice.
As there are at least 3 diﬀerent purposes for identifying the
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CD34 molecule, this in fact represents 3 diﬀerent CD34
tests, each with its own purpose, test performance char-
acteristics, validation requirements and scoring/readout
criteria; this holds true even if for some (diﬀerent) purposes
the CD34 IHC protocol remains the same (Fig. 1).28–31
The question of whether there is such a thing as a
“multipurpose” IHC test inevitably arises and it is an im-
portant question. The answer is that there can be no such
thing as a “multipurpose IHC test” for the reason that
purpose is intrinsic to the very deﬁnition of any laboratory
test including all IHC tests. However, an IHC protocol
may certainly be multipurpose, where a single set of pro-
tocol conditions may be applied for diﬀerent IHC tests.
For example, it is possible that a single IHC protocol can
be used for the purpose of detecting PAX8 expression in
tumors of thyroid, kidney, and Mu¨llerian origin. However,
it is also possible that an IHC protocol designed to detect
PAX8 expression in thyroid tumors, where expression
levels are usually high, may fail to detect expression of
PAX8 in some other tumors with possibly lower expression
levels. Therefore, in the development of this hypothetical
PAX8 IHC assay, we would need to consider whether the
assay’s analytical sensitivity is ﬁt for each of our various
purposes. Although in current clinical practice the majority
of IHC protocols are performed under the assumption that
they are “multipurpose,” it is unlikely that many such
protocols were actually validated for all purposes for which
they are being used. Data from proﬁciency testing (Nor-
diQC, UK NEQAS, etc.) clearly indicates that validation
of “multipurpose” IHC protocol is challenging and not
uniformly performed by all laboratories. For example, for
PAX8, run 42 2014 in the NordiQC program, 25% of the
participating laboratories were able to demonstrate PAX8
in the high level expressing sample but produced a false
negative result in the sample with low level expression such
as clear cell renal cell carcinoma.32
It is of utmost importance that should any new
purpose arise for which an existing IHC protocol will be
used, it should be carefully re-evaluated and the need for
additional validation carefully considered.
“PURPOSE,” “INTENDED USE,” “USE,” AND
“FIT-FOR-PURPOSE”
The “purpose” of an IHC test may be deﬁned as the
“intended use at the time the test was developed.” However
the “purpose” for which a test was developed and validated
by the clinical laboratory may not necessary be the same as
the “use” that an ordering physician has in mind (eg, a staﬀ
pathologist) after the test has been made available for clinical
practice; if such situations arise, then “current use(s)” would
no longer align with “intended use at the time the test was
developed” (ie, original purpose). For example, the ALK
IHC test that was developed and validated for the purpose
of detecting anaplastic large cell lymphoma has been “used”
to detect ALK expression in non–small cell lung cancer.
However, initial attempts resulted in unacceptably low sen-
sitivity because the 2 entities harbor different gene re-
arrangements and have different protein expression levels; as
such, it was discovered that the detection of ALK expression
in lung cancer may require an IHC protocol of higher sen-
sitivity than that required for ALK expression in lympho-
ma.33 In addition, the readout criteria (eg, cutoff values,
etc.), which are quite different in lymphomas and non–small
cell lung cancer, also must be adapted to reliably predict the
clinical relevance.34–36 Therefore, for IHC tests, “purpose”
and “intended use at the time the test was developed” reflect
test development, which is within the domain of the labo-
ratory. In contrast, “use” in a more general sense relates to
clinical practice, which may be different from the original
“intended use” and is within the domain of the practicing
physician (eg, pathologist and/or treating physician). The
concept of “fit-for-purpose” has evolved to address such
possible confusion. “Fit-for-purpose” describes an assay that
has been successfully validated for the intended use at the
time the assay was developed, combining both laboratory
and clinical definitions.10,37 It is expected that the new bio-
markers will be fit-for-purpose as there are high expectations
that the biomarkers will improve diagnosis, define disease
subsets that may differ in response, define individual varia-
bility in the drug’s molecular target, and provide early clues
regarding response to therapy.38,39
TABLE 1. Different Purposes of the CD34 Immunohistochemistry (IHC) Test
IHC Test Field Purpose Readout
CD34 Dermatopathology and
soft tissue pathology
To distinguish solitary ﬁbrous tumor (CD34+)
from desmoplastic mesothelioma (CD34), or
To distinguish dermatoﬁbroma (CD34) from
dermatoﬁbrosarcoma protuberans (CD34+)
Positive vs. negative
CD34 Hematopathology To identify CD34+ blasts in bone marrow tissue
biopsy, to distinguish between acute leukemia
(>20% CD34+ blasts) and myelodysplastic
syndrome (MDS) as well as aplastic anemia (no
or decreased CD34+ blasts) from hypoplastic
MDS (increased CD34+ cells)
Enumeration of CD34+ blasts
Counting 500 to 1000 cells
Cutoﬀ points at 5% (increased blasts),
10% (accelerated phase of
myeloproliferative neoplasms or
diagnosis of MDS-II), and >20%
(acute leukemia)
CD34 Vascular density To determine degree of vascularization IA using microvessel density algorithm
IA indicates image analysis.
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From the perspective of the laboratory, purpose is
the reason for which the laboratory sets up the test and is
what dictates how the laboratory performs the validation
of that test. It is therefore important that prior to the
development, calibration, and validation of a new IHC
assay, there should be coordination between the labo-
ratory director and the end user(s) to ensure that intended
use (ie, purpose, which will drive validation requirements)
and actual use will be properly aligned. Whether an assay
that has been introduced into clinical practice in this
manner will ever be “used” for a diﬀerent purpose than
originally intended is unknown to both the laboratory
director and to end user(s). However, should such a sce-
nario arise (eg, a diﬀerent clinical use of an existing as-
say), a new “ﬁt-for-purpose” validation process would be
required.
Lastly, an important point to note regarding
“purpose” is that in relation to clinical IHC testing,
“purpose” is not simply the in situ detection of a bio-
logical gene product in tissue sections. In order to be
meaningful, the purpose of any clinical IHC test must
always be accompanied by a medical context, because it is
this context that will impact the validation requirements
of a particular IHC test.
CLASSIFICATION OF IHC TESTS BASED ON FIT-
FOR-PURPOSE PRINCIPLES
A number of classiﬁcation schemes for diagnostic
tests have been introduced in diﬀerent regions of the
world as part of regulatory oversight to ensure appro-
priate testing for patient care.
The main principle underlying the various classi-
ﬁcation schemes is based on the degree of risk to patient
safety and public health. The degree of oversight for a test
should be commensurate with the perceived risk to the
patient.40,41 The Food and Drug Administration in the
United States (FDA) and International Medical Device
Regulators Forum have adopted this principle.42,43 An
approach based on the degree of risk to patient safety
translates into the domain of quality assurance, where the
test classiﬁcation dictates diﬀering levels of stringency in
relation to requirements for validation, documentation,
and reporting. From a quality assurance perspective,
approaching the classiﬁcation of tests in this manner en-
sures that the “ﬁt-for-purpose” principle is always kept in
mind and that the test will be conducted in a manner that
considers both the needs of the user and the eﬀect of the
test result on the patient.
TYPE 1-IHC AND TYPE 2-IHC TESTS
The Canadian Association of Pathologists (CAP-
ACP) has proposed 2 classes of IHC tests based on the
end user of the IHC results: class I (pathologist end user)
and class II (treating physician end user) IHC tests.44 The
current paper adheres to the same principles but oﬀers an
update in terminology in order to highlight and clarify the
role of IHC test classiﬁcation in quality assurance. IHC
tests where the test is read by the pathologist, and the
results of the readout used by that pathologist for his/her
diagnostic practice are termed “pathologist end user IHC
tests” (type 1-IHC tests) (Table 2).45 IHC tests where the
pathologist’s readouts are used by a treating physician in
order to determine patient management, are “treating
physician end user IHC tests” (type 2-IHC tests). The
latter include prognostic tests, predictive tests, and
screening tests (a special subtype of diagnostic tests) that
are relevant for patient management (Table 2).
Figure 1 illustrates similarities and diﬀerences be-
tween type 1 and type 2 tests.
Although these deﬁnitions of type 1-IHC and type
2-IHC tests have broad correlation to various regulatory
frameworks, this terminology is introduced to avoid the
use of the term “class,” which has been deﬁned on a
diﬀerent basis. The goal is to avoid potential confusion
with FDA classiﬁcation of IHC devices and other test
classiﬁcation schemes in various countries that address
risk and refer to industry and devices rather than IHC
tests and how these are actually used by pathologists and/
or treating physicians. The comparison with classiﬁcation
schemes used by various regulatory agencies is shown
in Table 3.41,42,44,46,47
THE IHC PROTOCOL, THE “READOUT” AND
THE”INTERPRETATION”
The IHC test encompasses preanalytic, analytic,
and postanalytic phases. Figure 1 illustrates these diﬀer-
ent components of the IHC test. The analytical phase of
the IHC test is complex and it consists of various com-
ponents of the IHC protocol as well as the “readout” of
the generated IHC slide. There is an essential diﬀerence
between IHC testing and other biomarker testing meth-
ods. As noted above, IHC tests are for the most part
descriptive, or at best quasiquantitative, and the readout
is the culmination of a morphologic analysis of an IHC
slide by a pathologist, who assesses the presence and lo-
calization of signals, evaluates cutoﬀ points between what
TABLE 2. The Classification of Immunohistochemistry (IHC)
Tests From the Perspective of the End User
Test Category
User-Based
Classiﬁcation Example
Diagnosis in symptomatic
patients (diagnostic)
Pathologist
(type 1-
IHC)
S100, VIM, CD45 and
PAN-CK in diagnosis of
unknown primary tumor
Disease screening (for an
additional disorder) in
symptomatic patients
(diagnostic)
Treating
physician
(type 2-
IHC)
MLH1, MSH2, MSH6 and
PMS2 in colorectal
cancer patients being
screened for Lynch
syndrome
Prognosis of a diagnosed
disease (prognostic)
Treating
physician
(type 2-
IHC)
CD10, Bcl-6, and MUM1
for cell of origin in
diﬀuse large B-cell
lymphoma
Predictive of treatment
response or adverse
reaction (predictive)
Treating
physician
(type 2-
IHC)
ER, PR, HER2 for breast
cancer, HER2 for gastric
cancer
Appl Immunohistochem Mol Morphol  Volume 25, Number 1, January 2017 Fit-for-purpose Approach to IHC
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constitutes a positive and negative signal, and counts
positive cells, or uses other methods of scoring as ap-
propriate.48,49 In essence, the IHC test is always descrip-
tive, even when it is possible to provide information in a
quantitative format.
It takes years of training and experience as well as
focused continuing medical education to become proﬁ-
cient at reading IHC slides. For certain biomarkers, the
readout criteria to determine whether a test is “positive”
or “negative” may be seemingly straight forward (eg,
reading thyroid transcription factor-1 IHC slides in lung
cancer); however, it may also be very complex such as
when multiple criteria are incorporated in the readout (eg,
reading HER2 IHC slides) or when evaluating for vas-
cular invasion, microinvasion, micrometastasis, where
higher levels of experience are required for proper read-
out.50–54 This practice is clearly in contrast to other bio-
markers for which readouts are performed by automated
instruments of diﬀerent types (nephelometry, colorimetric
methods, mass spectrometry, ﬂow cytometry, etc.).
Computer aided digital image analysis (IA) has been in-
troduced for readout of IHC slides, with the intent of
improving reproducibility of results.55–58 IA currently still
requires time from a pathologist to determine what part
of the tissue and what cells will be scored as well as which
algorithms are applicable for a given readout; a number
of these algorithms have been approved by the FDA and
other organizations for clinical use.59 In addition, the
approval of whole slide imaging for primary diagnosis,
already eﬀected in Europe and Canada, and under active
trial in the United States, surely will impact the growth of
computer-assisted morphometry and analysis of IHC in
the near future. Nevertheless, at present, IA should be
viewed as assistive technology that helps, but currently
cannot replace, pathologists in generating the readout
from an IHC slide.60 The analytical phase of IHC testing
is completed by the readout of the IHC slide.
Interpretation of the readout occurs in the post-
analytical phase of IHC testing.61 For type 1-IHC tests, it
is the pathologist end user who interprets the readout
results. An example of this would be a clinical case of
“tumor of unknown origin” where IHC testing was or-
dered to help identify the potential primary site of a
metastatic tumor deposit. A typical readout result might
be that cytokeratin 20 and CDX2 are positive and cyto-
keratin 7 and thyroid transcription factor-1 are negative;
TABLE 3. Comparison of Immunohistochemistry (IHC) Classification Schemes of IHC Tests by Regulatory Agency and
Classification Based on Clinical Practice
Regulation of
Test Manufacturers Intention Class
Clinical Practice
(Nearest Correlate)
FDA For regulating manufacturers of tests Class 1 Type 1-IHC
Class 2 Type 2-IHC
Class 3 Type 2-IHC
Health Canada For regulating manufacturers of tests Class 1 Type 1-IHC
Class 2 Type 2-IHC
Class 3 Type 2-IHC
Class 4 Type 2-IHC
EU In-vitro Diagnostic Regulation For regulating manufacturers of tests Class A NA
Class B NA
Class C Type 1-IHC, type 2-IHC
Class D Type 2-IHC
Canadian Association of Pathologists Guidance for clinical practice Class 1 Type 1-IHC
Class 2 Type 2-IHC
FDA indicates Food and Drug Administration in the United States; NA, not available.
ANALYTICAL 
PHASE
IHC Protocol
PRE-ANALYTICAL 
PHASE
POST-ANALYTICAL 
PHASE
IHC Readout 
Pathologist 
+/- Image 
Analysis
TYPE 1-IHC
Pathologist Interpretation
TYPE 2-IHC 
Treating Physician Interpretation
Tissue Processing
FIGURE 1. The phases of IHC testing and the dual role of the pathologist in the analytical and postanalytical phases. The
pathologist performs the readout (with or without assistance by image analysis) and is also the end user for type 1-IHC testing.
IHC indicates immunohistochemistry.
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the subsequent interpretation by the pathologist end user
(ie, the sign-out pathologist) may then reasonably be
“consistent with adenocarcinoma with intestinal diﬀer-
entiation.”62 The sign-out pathologist in this example
may or may not choose to report the detailed readout of
the IHC results, but will certainly report his/her inter-
pretation of the readout results. It is also worth noting
that for type 1-IHC tests, which by current convention are
both “read” and “interpreted” by the same pathologist
(ie, the sign-out pathologist), it may appear as though
readout and interpretation are concurrent; in practice
they may occur very close together, but the interpretation
is necessarily subsequent to the readout.
For type 2-IHC tests, it is the treating physician end
user who interprets the readout results in the context of
clinical actions. An example would be a treating physician
who receives IHC results for a patient with carcinoma of
the breast stating that the sampled tumor cells are
“strongly positive for estrogen receptor and progesterone
receptor and negative for HER2”; the treating physician
may then interpret the readout results as indicating that
“the patient is a good candidate for hormonal therapy.”63
When a pathologist reports a test result as
“positive” versus “negative,” the presumption is that the
pathologist is following predetermined scoring criteria
using predetermined scoring or cut oﬀ points, extending
beyond the usual meaning of “interpretation.” As the
term “interpretation” is inherently associated with post-
analytical phase, it is important that any readout as a part
of analytical phase, irrespective of its complexity, is not
called “interpretation.” Moreover, in some type 2 tests,
pathologists may also contribute more directly to the
clinical interpretation that will eventually help the treat-
ing physician in patient management. For example in
IHC testing for DNA mismatch repair deﬁciency, path-
ologists may provide additional interpretation of unusual
patterns (eg, when reporting discordant subclonal pat-
terns) that directly impact upon how the treating physi-
cian interprets and applies the results in treatment.64
This paper seeks to apply the standardized termi-
nology for laboratory testing in the context of IHC; thus
“readout” is considered to be part of the analytic phase,
whereas “interpretation” is linked to the postanalytical
phase.65 For clarity, the term “readout” is applied to the
process whereby a pathologist using high-level skills
“reads” the IHC slide (ie, produces a result), before a
closely related but subsequent process in which the
readout (or IHC result) is interpreted in the context of
pathology diagnosis or clinical scenario. Clearly, pathol-
ogists are “interpreting” (in the more general use of the
word) all visual cues present in the IHC slides in arriving
at the most accurate readout (result) (eg, assessing signal
intensity, localization, “texture,” and other signal pa-
rameters in conjunction with controls, excluding various
type of artifacts, etc.). However, all subsequent mental
processing of the information incorporated into the
“readout” is, by analogy with other forms of laboratory
testing, properly considered to be “interpretation” by the
pathologist (for type 1 IHC results) for diagnostic
purposes or by the treating physician (for type 2 IHC
results) for decisions directly relevant to patient treat-
ment. With this approach, the readout is properly iden-
tiﬁed as a part of the analytical phase, just like it is in any
other laboratory test (eg, nephelometry, mass spectrom-
etry, etc.).66,67 Furthermore, this approach also applies to
IA; IA is intuitively accepted as “readout,” not as
“interpretation” because it is performed by machines ex-
ecuting automated algorithms rather than by a living
person.
CONCLUSIONS
Biomarker testing by IHC is critical to patient care
in the era of precision medicine. The IHC test is purpose-
driven and purpose-deﬁned. In today’s world, an IHC test
is only meaningful when it is linked with a speciﬁc pur-
pose for which it has been developed.
Part 1 of this 4-part series highlights the following:
1. The purpose of an IHC test is intrinsic to the test itself;
if it is discovered that the current use of the test is
diﬀerent from its original purpose, the new purpose
requires consideration of whether or not a new ﬁt-for-
purpose development and validation process is needed.
2. The result of an IHC test is not the IHC slide itself
with the signal pattern that emerges on the tissue after
development of the reaction product; rather, it is the
readout of that signal pattern. This readout is
performed by a pathologist, sometimes with the
assistance of computer aided IA. Readout of IHC
slides does require intellectual activity, observation
and judgment, but this process should be considered as
separate from interpretation of laboratory results in a
strict sense, which is about what the result “means.”
3. The readout (test result) is a part of the analytical
phase of IHC testing and is distinct from interpreta-
tion of the meaning, signiﬁcance and utility of the test
result. Generally, interpretation is a postanalytic test
element performed by a pathologist (for diagnosis) or
a treating physician (± pathologist) (for treatment
decisions).
4. Using a ﬁt-for-purpose approach, IHC tests can be
classiﬁed as “type 1-IHC” tests or “type 2-IHC” tests
based on the end-user.
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